靶向IGF2重编程肿瘤微环境以增强病毒免疫治疗
本研究通过RNA测序发现溶瘤单纯疱疹病毒1型(oHSV)治疗后IGF2分泌上调,14例复发胶质母细胞瘤(GBM)患者中10例(71.4%;P=.0020)IGF2表达显著上调。耗竭IGF2可增强oHSV体外杀伤并改善脑转移瘤小鼠生存;新型oHSV-D11mt分泌IGF2R结构域11诱饵受体,阻断IGF2后增加细胞毒性、减少中性粒细胞/PMN-MDSC浸润并增加CD8+细胞毒性T淋巴细胞浸润,延长GBM或BCBM荷瘤小鼠生存。
要点
- oHSV治疗后IGF2分泌上调,14例复发GBM中10例(71.4%;P=.0020)IGF2表达显著上调。
- 耗竭IGF2增强oHSV体外杀伤肿瘤细胞并改善BCBM小鼠生存。
- oHSV-D11mt通过IGF2RD11mt阻断IGF2,增强病毒免疫治疗疗效。
核心结论
- 本研究首次报道oHSV诱导分泌的IGF2在oHSV治疗抵抗中起关键作用,oHSV-D11mt作为有前景的治疗进展可克服该抵抗以增强病毒免疫治疗。
研究设计与样本
- 采用RNA测序鉴定oHSV抵抗的分子靶点,并使用颅内人源或鼠源胶质瘤或乳腺癌脑转移(BCBM)荷瘤小鼠模型阐明oHSV治疗诱导抵抗的机制。
主要发现
- 转录组分析鉴定IGF2为oHSV治疗后顶级分泌蛋白之一。
- 14例复发GBM患者接受oHSV rQNestin34.5v.2治疗后,10例(71.4%;P=.0020)IGF2表达显著上调(ClinicalTrials.gov,NCT03152318)。
- 耗竭IGF2显著增强oHSV介导的体外肿瘤细胞杀伤并改善BCBM荷瘤小鼠生存。
- IGF2RD11mt选择性阻断IGF2显著增加细胞毒性、减少oHSV诱导的中性粒细胞/PMN-MDSC浸润、减少免疫抑制/促血管生成细胞因子分泌,同时增加CD8+细胞毒性T淋巴细胞(CTL)浸润,延长GBM或BCBM荷瘤小鼠生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The FDA approval of oncolytic herpes simplex-1 virus (oHSV) therapy underscores its therapeutic promise and safety as a cancer immunotherapy. Despite this promise, the current efficacy of oHSV is significantly limited to a small subset of patients largely due to the resistance in tumor and tumor microenvironment (TME). METHODS: RNA sequencing (RNA-Seq) was used to identify molecular targets of oHSV resistance. Intracranial human and murine glioma or breast cancer brain metastasis (BCBM) tumor-bearing mouse models were employed to elucidate the mechanism underlying oHSV therapy-induced resistance. RESULTS: Transcriptome analysis identified IGF2 as one of the top-secreted proteins following oHSV treatment. Moreover, IGF2 expression was significantly upregulated in 10 out of 14 recurrent GBM patients after treatment with oHSV, rQNestin34.5v.2 (71.4%; P = .0020) (ClinicalTrials.gov, NCT03152318). Depletion of IGF2 substantially enhanced oHSV-mediated tumor cell killing in vitro and improved survival of mice bearing BCBM tumors in vivo. To mitigate the oHSV-induced IGF2 in the TME, we constructed a novel oHSV, oHSV-D11mt, secreting a modified IGF2R domain 11 (IGF2RD11mt) that acts as IGF2 decoy receptor. Selective blocking of IGF2 by IGF2RD11mt significantly increased cytotoxicity, reduced oHSV-induced neutrophils/PMN-MDSCs infiltration, and reduced secretion of immune suppressive/proangiogenic cytokines, while increased CD8 + cytotoxic T lymphocytes (CTLs) infiltration, leading to enhanced survival in GBM or BCBM tumor-bearing mice. CONCLUSIONS: This is the first study reporting that oHSV-induced secreted IGF2 exerts a critical role in resistance to oHSV therapy, which can be overcome by oHSV-D11mt as a promising therapeutic advance for enhanced viro-immunotherapy.
引用
- Noh MH, Kang JM, Miller AA, et al. Targeting IGF2 to reprogram the tumor microenvironment for enhanced viro-immunotherapy. Neuro Oncol. 2024. PMID: 38853689. doi:10.1093/neuonc/noae105
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。